or Try an Advanced Search...

    Liver Disease Stocks List

    Symbol Grade Name % Change
    BLTE B Belite Bio, Inc. -0.10
    MIRM B Mirum Pharmaceuticals, Inc. -0.48
    ALGS C Aligos Therapeutics, Inc. 8.74
    GILD C Gilead Sciences, Inc. 1.27
    GALT C Galectin Therapeutics Inc. -3.37
    HEPA C Hepion Pharmaceuticals, Inc. -0.62
    TARA D ArTara Therapeutics, Inc. -0.87
    ALNY D Alnylam Pharmaceuticals, Inc. -0.80
    GRI D GRI Bio, Inc. 7.82
    GYRE D Gyre Therapeutics, Inc. -8.99
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
    Related Stock Lists: Medicine Biopharmaceutical Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Alcohol Chronic Liver Diseases Clinical Medicine Coronavirus Drug Development Gilead Sciences Hepatitis B Hepatology Hepatotoxins Lipid Liver Fibrosis Pulmonary Arterial Hypertension Tenofovir Disoproxil Acid Acute Intermittent Porphyria

    Related ETFs - A few ETFs which own one or more of the above listed Liver Disease stocks.

    Symbol Grade Name Weight
    BBH D Market Vectors Biotech ETF 14.47
    IBBQ D Invesco Nasdaq Biotechnology ETF 13.44
    IBB D iShares Nasdaq Biotechnology Index Fund 13.25
    BIB F ProShares Ultra Nasdaq Biotechnology 10.11
    BIS B ProShares UltraShort Nasdaq Biotechnology 9.01
    View all Liver Disease ETFs...
    Compare ETFs
    Compare BBH to BIB Compare IBBQ to BIB Compare IBBQ to IBB

        Liver Disease Stocks Recent News

        Date Stock Title
        Nov 21 GRI GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
        Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
        Nov 20 BLTE Belite Bio: Interesting Science, But Quite A Few Worries
        Nov 19 ALGS Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
        Nov 18 ALNY Alnylam releases encouraging interim data on nucresiran for ATTR amyloidosis
        Nov 18 GILD Gilead’s Livdelzi shows promise in PBC clinical trial
        Nov 18 ALNY ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
        Nov 18 GALT Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
        Nov 18 ALNY Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment
        Nov 17 ALNY Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose
        Nov 15 TARA Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology
        Nov 15 GILD Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
        Nov 15 GILD Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
        Nov 15 MIRM Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
        Nov 15 GRI GRI Bio reports 9M results
        Related Industries: Biotechnology Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Health Information Services
        Related Stock Lists: Medicine Biopharmaceutical Hepatitis Non Alcoholic Fatty Liver Disease Steatohepatitis Alcohol Chronic Liver Diseases Clinical Medicine Coronavirus Drug Development Gilead Sciences Hepatitis B Hepatology Hepatotoxins Lipid Liver Fibrosis Pulmonary Arterial Hypertension Tenofovir Disoproxil Acid Acute Intermittent Porphyria
        Liver Disease

        Liver disease (also called hepatic disease) is a type of damage to or disease of the liver. Whenever the course of the problem lasts long, chronic liver disease ensues.

        More about Liver Disease
        Browse All Tags